JP6865211B2 - 改変された炭疽毒素保護抗原 - Google Patents

改変された炭疽毒素保護抗原 Download PDF

Info

Publication number
JP6865211B2
JP6865211B2 JP2018510419A JP2018510419A JP6865211B2 JP 6865211 B2 JP6865211 B2 JP 6865211B2 JP 2018510419 A JP2018510419 A JP 2018510419A JP 2018510419 A JP2018510419 A JP 2018510419A JP 6865211 B2 JP6865211 B2 JP 6865211B2
Authority
JP
Japan
Prior art keywords
amino acid
cells
tumor
seq
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018510419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527926A5 (enExample
JP2018527926A (ja
Inventor
リュー、シ−フィ
エイチ． レップラ、ステファン
エイチ． レップラ、ステファン
エイチ． ブッゲ、トーマス
エイチ． ブッゲ、トーマス
エヌ． ウェイン、アレキサンダー
エヌ． ウェイン、アレキサンダー
イー． ピーターズ、ダイアン
イー． ピーターズ、ダイアン
リュー、ジエ
チェン、クアン−ホア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2018527926A publication Critical patent/JP2018527926A/ja
Publication of JP2018527926A5 publication Critical patent/JP2018527926A5/ja
Application granted granted Critical
Publication of JP6865211B2 publication Critical patent/JP6865211B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018510419A 2015-08-27 2016-08-25 改変された炭疽毒素保護抗原 Active JP6865211B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562210771P 2015-08-27 2015-08-27
US62/210,771 2015-08-27
US201662323218P 2016-04-15 2016-04-15
US62/323,218 2016-04-15
PCT/US2016/048706 WO2017035359A1 (en) 2015-08-27 2016-08-25 Modified anthrax toxin protective antigen

Publications (3)

Publication Number Publication Date
JP2018527926A JP2018527926A (ja) 2018-09-27
JP2018527926A5 JP2018527926A5 (enExample) 2019-10-03
JP6865211B2 true JP6865211B2 (ja) 2021-04-28

Family

ID=56943920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018510419A Active JP6865211B2 (ja) 2015-08-27 2016-08-25 改変された炭疽毒素保護抗原

Country Status (7)

Country Link
US (1) US10835593B2 (enExample)
EP (1) EP3341393B1 (enExample)
JP (1) JP6865211B2 (enExample)
KR (1) KR20180073555A (enExample)
CN (1) CN108350041A (enExample)
AU (1) AU2016311429C1 (enExample)
WO (1) WO2017035359A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6865211B2 (ja) 2015-08-27 2021-04-28 アメリカ合衆国 改変された炭疽毒素保護抗原
CN120555349A (zh) 2018-11-16 2025-08-29 拉帕治疗有限公司 使用诱导性调节性T（iTREG）细胞进行的ALS治疗
EP4150060A4 (en) * 2020-05-13 2024-06-19 Rapa Therapeutics, LLC TREATMENT OR PREVENTION OF PRO-INFLAMMATORY DISEASES OR CONDITIONS WITH INDUCED REGULATORY T (IT) CELLS
JP7648075B2 (ja) * 2020-11-27 2025-03-18 株式会社ダイセル 融合タンパク質
CN117343942B (zh) * 2023-12-06 2024-02-13 南京市食品药品监督检验院 一种pagA重组蛋白及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233495T3 (es) 1999-09-24 2005-06-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Proteinas antigenicas protectoras contra toxinas de antrax mutadas que se dirigen especificamente a celulas que contienen altas cantidades de metaloproteinasas de la superficie celular o receptores del activador de plasminogeno.
US7601351B1 (en) * 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
US20100168012A1 (en) 2006-12-14 2010-07-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Human cancer therapy using engineered matrix metalloproteinase-activated anthrax lethal toxin that targets tumor vasculatuture
CN101215568B (zh) * 2008-01-18 2010-06-23 畿晋庆三联（北京）生物技术有限公司 抗炭疽多肽及其应用与制备方法
WO2014134187A1 (en) * 2013-02-26 2014-09-04 The Regents Of The University Of California Compositions and methods for the treatment of cancer
WO2014205187A1 (en) 2013-06-20 2014-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cytolethal distending toxin subunit b conjugated or fused to bacillus anthracis toxin lethal factor
AU2014324901A1 (en) 2013-09-25 2016-05-19 Axcella Health Inc. Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control
JP6865211B2 (ja) 2015-08-27 2021-04-28 アメリカ合衆国 改変された炭疽毒素保護抗原

Also Published As

Publication number Publication date
CA2996767A1 (en) 2017-03-02
EP3341393B1 (en) 2021-03-03
WO2017035359A1 (en) 2017-03-02
AU2016311429C1 (en) 2021-10-07
KR20180073555A (ko) 2018-07-02
EP3341393A1 (en) 2018-07-04
US10835593B2 (en) 2020-11-17
AU2016311429A1 (en) 2018-04-19
CN108350041A (zh) 2018-07-31
US20180250376A1 (en) 2018-09-06
JP2018527926A (ja) 2018-09-27
AU2016311429B2 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
JP5904985B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
JP6865211B2 (ja) 改変された炭疽毒素保護抗原
Dubois et al. Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action
JP7724601B2 (ja) 腫瘍溶解性ウイルス療法
CN105008397B (zh) 作为治疗试剂的Gla结构域
JP2007506789A (ja) Ｉｌ−２１を用いた自己免疫疾患の治療方法
JP7080053B2 (ja) 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
CN111050784B (zh) 截短的豚鼠l-天冬酰胺酶变体及其使用方法
CN102341407A (zh) 作为补体抑制剂的经修饰的omci
JP2023506681A (ja) 免疫調節のための化合物
AU2020307688B2 (en) Combination cancer immunotherapy
EP4531862A2 (en) Combination of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of use
CA2996767C (en) Modified anthrax toxin protective antigen
JP4273234B2 (ja) チオレドキシン改変体
CN121152635A (zh) 用于增强细胞疫苗的免疫原性的方法
WO2018230628A1 (ja) ファブリー病治療用医薬の組合せ物及びその利用

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20180802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200915

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210316

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210405

R150 Certificate of patent or registration of utility model

Ref document number: 6865211

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250